Resources

An experimental Merck obesity drug helped patients lose weight and burn up calories, but at higher doses caused psychiatric side effects similar to those that prevented U.S. approval of a similar Sanofi-Aventis drug, researchers said.

A new study suggests that, “The neighborhood people live in might play a role in their risk of developing type 2 diabetes.

MODY: An Insulin Sensitive Form Of Monogenic Diabetes Often Misdiagnosed As Type 2 Janet Ruhl, Type 2 1998-2006, MODY 2006-2007 MODY: An Insulin Sensitive Form Of Monogenic Diabetes Often Misdiagnosed As Type 2 Janet Ruhl, Type 2 1998-2006, MODY 2006-2007 NIH statistics reveal that almost 20% of all people diagnosed …

Everyday hospitals are closing down their diabetes education programs making it harder for our patients to get the knowledge to manage their diabetes. You may not know this but in 1997 when funding was made for education for patients, the recognized experts, CDE’s were not included in the bill!! Now …

A study published online in the journal Vaccine found the influenza vaccine had no impact on emergency admissions in the elderly.

French researchers report in the American Journal of Clinical Nutrition for December that, two months of daily fish oil supplements reduces adiposity and atherogenic markers in women with type 2 diabetes.

According to recent research published in the journal Diabetes Care, “In the Indian Diabetes Prevention Program (IDPP), a 3-year randomized, controlled trial, lifestyle modification (LSM) and metformin helped to prevent type 2 diabetes in subjects with impaired glucose tolerance (IGT).

A daily glass of wine with dinner for those with type 2 diabetes lowers fasting plasma glucose (FPG), Israeli researchers report in the December issue of Diabetes Care.

A new specific peroxisome proliferator-activated receptor (PPAR) modulator has demonstrated promise in a new study reported in November issue of Diabetes.

Takeda Pharmaceutical Company Limited announced today that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.